^
Association details:
| Biomarker: | NTRK1 fusion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | CS3002 (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4844: CS3002, a novel CDK4/6 inhibitor with unique kinase inhibition spectrum which may expand indications beyond breast cancer and delay acquired drug resistance
Published date:
05/15/2020
Excerpt:
...CS3002 demonstrated high activity in cell lines harboring NTRK1 fusion that were otherwise insensitive to CDK4/6 inhibitors….Across a panel of 19 AML cell lines, CS3002 demonstrated a similar sensitivity profile to gilteritinib (an approved FLT-3 inhibitor), but overall higher sensitivity compared to palbociclib.
DOI:
10.1158/1538-7445.AM2020-4844
